Meeting
2018 ASCO Annual Meeting
Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo).
Authors
Elisa A. Rozeman
Netherlands Cancer Institute, Amsterdam, Netherlands
Elisa A. Rozeman , Alexander Christopher Jonathan Van Akkooi , Alexander M. Menzies , Myles Smith , Richard A. Scolyer , Loes M. Pronk , Maria Gonzales , Christoph Hoeller , Johan Hansson , James M. G. Larkin , Georgina V. Long , Christian U. Blank
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT02977052
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS9606)
DOI
10.1200/JCO.2018.36.15_suppl.TPS9606
Abstract #
TPS9606
Poster Bd #
427b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Survival update of neoadjuvant ipilimumab + nivolumab in macroscopic stage III melanoma: The OpACIN and OpACIN-neo trials.
First Author: Judith M. Versluis
Poster
2017 ASCO Annual Meeting
Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo).
First Author: Elisa A. Rozeman
Poster
2020 ASCO Virtual Scientific Program
Personalized combination of neoadjuvant domatinostat, nivolumab and ipilimumab in macroscopic stage III melanoma patients stratified according to the interferon-gamma signature: The DONIMI study.
First Author: Irene L.M. Reijers
Poster
2020 ASCO Virtual Scientific Program
A phase II study of neoadjuvant pembrolizumab and lenvatinib for resectable stage III melanoma: The neopele study.
First Author: Maria Gonzalez